NACDS announces promotion of Roy McGrath, Alex Adams
ARLINGTON, Va. — The National Association of Chain Drug Stores announced on Friday the promotions of two staff members, that were effective March 1.
Roy McGrath has been promoted to VP of business development and conventions, from director of business development and conventions.
Alex Adams has been promoted to VP of pharmacy programs for NACDS, and VP of NACDS Foundation research programs, from director of pharmacy programs.
McGrath has served NACDS in a number of capacities since joining NACDS in 1997, including manager, conference exhibits, and director, conference exhibits and registration. His promotion comes at an important time in NACDS’ conference programming. In his new role, he will lead initiatives to drive business opportunities for NACDS meetings and conferences, including the inaugural NACDS Total Store Expo taking place Aug. 10 to 13 in Las Vegas. McGrath will continue to advance business initiatives to bring together trading partners across the industry including pharmacy, consumer goods, supply chain, logistics, technology and more for the NACDS Total Store Expo. He will continue to report to Jim Whitman, SVP, member programs and services.
As a pharmacy student at the University of Toledo, Adams served as a pharmacy rotation student before joining NACDS in 2009 as director, pharmacy programs. In his new role with NACDS, he will lead and develop pharmacy programming initiatives to continue the momentum for NACDS’ new pharmacy care and patient advocacy department. In addition, in his new NACDS Foundation role, Adams will work to further one of the Foundation’s core missions in advancing public health through research to help improve patient health and quality of life. He will continue to report to Kathleen Jaeger, SVP, pharmacy care and patient advocacy and president of the NACDS Foundation in both of his new roles.
"We are pleased to recognize the hard work and dedication of both Roy and Alex within their respective departments at NACDS and the NACDS Foundation," stated Steve Anderson, NACDS president and CEO. "Roy’s service to NACDS the last sixteen years demonstrates his commitment to providing business and educational opportunities for NACDS members at our meetings and conferences. As a pharmacist, Alex’s passion and commitment to community pharmacy is personified in his work on behalf of NACDS, its members and the Foundation. We look forward to their continued success in their new roles."
NACDS RxImpact Day comes at a critical time for industry
Hundreds of community pharmacy executives, pharmacy students and other pharmacy advocates representing 41,000 chain pharmacies took to Capitol Hill last week for the 5th Annual NACDS RxImpact Day and conducted more than 400 meetings with U.S. senators and representatives.
With implementation of the Patient Protection and Affordable Care Act in 2014, Congress desperately needs to hear from a stakeholder that can actually save the system money. There is growing awareness on the Hill that for every $1 invested in MTM, you save $10 to $12 — the bill introduced this week by Sens. Pat Roberts and Kay Hagan to expand MTM is a strong demonstration of that.
"NACDS appreciates the leadership of Sens. Hagan and Roberts in spearheading this commonsense legislation, as well as the support of original cosponsors Sens. Brown, Franken, Johnson and Klobuchar. This bill can help patients understand the importance of taking their medications as prescribed,” stated NACDS president and CEO Steve Anderson in a prepared statement. “Innovative pharmacy services such as MTM help to improve patient health and healthcare affordability, especially for those suffering from chronic conditions such as diabetes, hypertension, asthma and other conditions.”
It is likely that legislation will draw more supporters in the weeks ahead, as NACDS members held more than 400 deskside meetings with members of Congress from their home districts, and MTM was one of three key talking points all RxImpact attendees came prepared to hammer home.
To make sure lawmakers got the message, Drug Store News produced the third edition of its RxImpact supplement profiling what community pharmacy is doing to advance patient care, lower costs, improve outcomes, and expand accessibility to quality care. The supplement was part of all RxImpact kits prepared as leave-behinds for members of Congress. The supplement was also hand-delivered to all members of the House and Senate.
The RxImpact Day event continues to grow in popularity. Participation was up 29% in 2013, with 34 companies attending (70% of industry), 38 states represented and 21 pharmacy schools.
FDA approves new packet version of AbbVie testosterone gel
CHICAGO — The Food and Drug Administration has approved a new pocket-sized packet option for a testosterone-replacement therapy made by AbbVie, the drug maker said Friday.
AbbVie announced the approval of the new version of AndroGel (testosterone) 1.62%, available in a packet containing 40.5 mg of testosterone in 2.5 g of gel and a packet with 20.25 mg of testosterone in 1.25 g of gel. The drug is used to raise testosterone levels in men with low or no testosterone, known as hypogonadism, estimated to affect nearly 14 million men in the United States.
The recommended starting dose for AndroGel 1.62% is 40.5 mg of testosterone applied once daily as directed. Physicians also can titrate administration up or down in 20.25-mg increments of testosterone based on serum total testosterone levels.